CD8A and melanoma: Additionally, a study in patients with melanoma or Merkle cell carcinoma demonstrated that a high frequency of circulating PD-1+ TIGIT+ CD8+ T cells after 1 month of anti-PD-1 was associated with an increased response rate and longer OS [18].